Company Overview and News
58 of 122 Monthly Paying (MoPay) Canadian (CAD) equities were "safer" by showing positive annual returns, and free cash flow yield greater than dividend yield.
CRIUF BPZZF CHP.UN RNW THO PPRQF CJR.B DREUF MR.UN EFRTF SBC DR.DB.A TRSWF TAHO ARESF SRRTF DR KWH.UN BTBIF PZRIF MFCSF DIR.UN CJREF SRT.UN PZA
Monthly paying (MoPay) dividend equities make dividend payouts to shareholders twelve times a year instead once, twice, or four times.
MGRUF FFN NAF.UN CRIUF MHIVF ATGFF RNW SOT.UN EFRTF AHOTF DR.DB.A DVVDF TRSWF ARESF DR CNDCF KWH.UN BK MFCSF FNCSF ALA
It's your September 2018 Monthly-Paid (MoPay) Small-Mid-Large Cap Dividend, Yield, Upsides, and Net Gains Report. Nano-Cap MoPays <$200M are not listed.
CRLFF CRIUF ORC MHIVF GLADO ATGFF AGNC TRSWF KWH.UN PSEC SCQ PBB MGRUF SCA CJ GOOD OXLCO OXLCN SCM GOODM GLAD SOT.UN RNW GOODN ECC ECCZ AHOTF ECCY GOODO GOODP SRRTF ARESF CGIFF PZRIF ?NHF? OXLC ECCB ARR ECCA SUNS GNL NHF ALA SRT.UN PZA
Here's your August 2018 Monthly-Paid (MoPay) Small-Mid-Large Cap Dividend, Yield, Upsides, and Net Gains Report. Nano-Cap MoPays are not listed.
MGRUF SCA CJ CRLFF CRIUF ORC MHIVF RA OXLCO OXLCN SCM GLADO ATGFF GLAD SOT.UN RNW ECC ECCZ AGNC AHOTF ECCY TRSWF SRRTF KWH.UN CGIFF ?NHF? PSEC OXLC ECCB ARR SCQ ECCA SUNS GNL NHF PBB ALA OPP SRT.UN
Monthly Paying (MoPay) dividend equities make dividend payouts to shareholders twelve times a year instead of just once, twice, or four times.
OSP CCAOF CNDCF GXOCF CJ FFN NAF.UN BK CRLFF CGIFF CRIUF MHIVF DVSPF LCS ATGFF RNW SOT.UN GXO EFRTF AHOTF FNCSF TRSWF
Good morning. My name is Christine, and I’ll be your conference operator today. At this time, I would like to welcome everyone to TransAlta Corporation Second Quarter 2018 Results Conference Call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks there will be a question-and-answer session. [Operator Instructions] Thank you.
RNW TAC TRSWF
Here's your July 2018 Monthly-Paid (MoPay) Small-Mid-Large Cap Dividend, Yield, Upsides, and Net Gains Report. Nano-Cap MoPays are not listed.
SCA "NHF" AD ALARF CRIUF ORC MHIVF RA OXLCO OXLCN SCM RNW CJR.B ECC ECCZ AGNC AHOTF DR.DB.A ECCY TRSWF DR CGIFF MFCSF PSEC OXLC ECCB CJREF SCQ ECCA SUNS GNL PBB
Innergex Renewable Energy (OTCPK:INGXF) (TSX:INE) is a Canada-based renewable power producer with a focus on hydroelectric, wind power and solar photovoltaic projects. The company is currently trading at a premium valuation to its peers. Its valuation is supported by its growth potential, long weighted-average PPA duration, and low maintenance expenditure. However, its debt load is quite high and rising benchmark bond yield can impact its share price.
RNW INE AXY NPIFF MGMXF INGXF MGMXD TRSWF TTM AQN NPI
2018-06-27 investorplace - 2
The 2020 Olympic Summer Games are to be held in Tokyo, Japan. The organizers of the games are planning to power the events with 100% renewable energy, which is great news for renewable energy stocks.
BAMGF TAC TPIC NAV RNW REGI EVA BAMKF NEE BAM TERP TRSWF BEP
NEW YORK, June 14 (Reuters) - * The Toronto Stock Exchange’s S&P/TSX rose 63.14 points, or 0.39 percent, to 16,328.96. * The biggest contributor to the TSX gain was Enbridge Inc adding 6.9 points to the index. The materials sector was the top sector contributor with a 15.9 point contribution to the upside. * Leading performers in the index were CES Energy Solutions Corp, up 8.5 percent, Yamana Gold Inc, up 5.
ENBBF YRI ACBFF IVN ENB FSM FVI ENB IVPAF ACB RNW AUY BDRPF EBBNF PFSCF TRSWF
CALGARY, Alberta, June 13, 2018 (GLOBE NEWSWIRE) -- TransAlta Renewables Inc. (“TransAlta Renewables” or the “Company”) (TSX:RNW) today announced that it has entered into an agreement with a syndicate of underwriters co-led by CIBC Capital Markets, RBC Capital Markets and Scotiabank, as joint bookrunners, for an offering, on a bought deal basis, of 11,860,000 common shares (“Common Shares”) in the capital of TransAlta Renewables at a price of $12.
RNW TAC TRSWF
In this article, we'll review all utilities in Canada that have increased their dividend for 5 or more years in a row and apply a dividend growth screen to try and find the best high-quality utility companies for further consideration. Turns out there was only one company that passed all of the criteria, but there are still a few other companies that are worthy of your consideration.
ACLTF CNUTF FTS EMRAF RNW VALU FTS TRI BIP CDUAF TRSWF CU
2018-05-21 seekingalpha - 1
Here's your April 2018 Monthly-Paid (MoPay) Small-Mid-Large Cap Dividend, Yield, Upsides, and Net Gains Reports. Nano-Cap MoPays are not listed.
SCA CCAOF CBL GOOD AD ALARF ORC OXLCO OXLCN SCM GOODM RNW GOODN CJR.B ECC ECCZ AGNC AHOTF DR.DB.A ECCY GOODO GOODP TRSWF DR MFCSF PSEC OXLC ECCB SCQ CJREF ECCA GNL PBB
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
as of ET